Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion

Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion

Cutaneous squamous cell carcinoma (CSCC) is the second most common skin malignancy in white-skinned populations. Only a minority of patients (<5%) develop advanced disease, but this is often difficult to treat and characterised by a poor prognosis. Cemiplimab, a fully human IgG4 monoclonal antibo...

Full description

Bibliographic Details
Main Authors: Giuseppe Argenziano, Maria Concetta Fargnoli, Fabrizio Fantini, Massimo Gattoni, Giulio Gualdi, Francesco Pastore, Giovanni Pellacani, Pietro Quaglino, Paola Queirolo, Teresa Troiani
Format: Article
Language:English
Published: SAGE Publishing 2022-01-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359211066272

Internet

https://doi.org/10.1177/17588359211066272

Similar Items